A
Abalos Therapeutics
Harnessing the power of arenaviruses in a differentiated immuno-virotherapy approach to fight cancer
About Abalos Therapeutics
Abalos Therapeutics GmbH is pioneering a novel approach to cancer treatment by leveraging the unique immune-stimulating properties of arenaviruses. The company operates in the biotechnology sector, focusing on developing innovative immuno-virotherapy solutions. Abalos targets cancer cells by using mammarenaviruses, which preferentially infect and proliferate within these cells, thereby inducing a robust and targeted immune response. This approach aims to activate all relevant immune cell types against both primary tumors and distant metastases.
The company's proprietary Fast Evolution Platform generates mammarenaviruses with optimized anti-tumoral properties, effectively reprogramming the immune system to eliminate malignant tumor tissue. Abalos serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, who are looking for cutting-edge cancer treatment solutions.
Abalos operates on a business model that includes research and development, clinical trials, and potential partnerships or licensing agreements with larger pharmaceutical companies. Revenue is generated through these partnerships, grants, and future sales of their therapeutic products once they receive regulatory approval.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 69.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Medical Research, Oncology, Medical & Healthcare, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Abalos Therapeutics is 950 monthly website visits, up 69.6% over the last three months. Abalos Therapeutics's team declined 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Abalos Therapeutics in the Düsseldorf ecosystem
The Abalos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Gründerfonds Ruhr
Boehringer Ingelheim Venture Fund
HTGF
NRW.BANK
Seventure Partners
Coparion- VIVentura BioMed Investors
Hx Bio Ventures- HCHealth for Life Capital
Boehringer Ingelheim
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abalos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abalos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










